613,028 Shares in Gossamer Bio, Inc. (NASDAQ:GOSS) Bought by Allostery Investments LP

Allostery Investments LP purchased a new position in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 613,028 shares of the company's stock, valued at approximately $555,000. Gossamer Bio comprises 0.6% of Allostery Investments LP's investment portfolio, making the stock its 24th biggest position. Allostery Investments LP owned 0.27% of Gossamer Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of GOSS. Opti Capital Management LP bought a new stake in shares of Gossamer Bio in the fourth quarter worth approximately $165,000. Silverarc Capital Management LLC raised its stake in Gossamer Bio by 9.3% during the 4th quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock valued at $5,583,000 after buying an additional 526,495 shares during the last quarter. Smith Moore & CO. lifted its holdings in shares of Gossamer Bio by 32.7% during the 4th quarter. Smith Moore & CO. now owns 300,000 shares of the company's stock valued at $271,000 after buying an additional 74,000 shares during the period. Geode Capital Management LLC grew its holdings in shares of Gossamer Bio by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock worth $2,037,000 after acquiring an additional 38,084 shares during the period. Finally, Monaco Asset Management SAM lifted its holdings in Gossamer Bio by 39.5% in the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock valued at $4,859,000 after acquiring an additional 1,520,721 shares during the period. 81.23% of the stock is owned by institutional investors.

Gossamer Bio Price Performance

Shares of GOSS stock traded up $0.07 on Monday, hitting $1.25. 2,188,180 shares of the stock traded hands, compared to its average volume of 1,581,437. The firm has a market cap of $284.03 million, a price-to-earnings ratio of -3.91 and a beta of 1.82. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The firm has a 50 day simple moving average of $1.07 and a two-hundred day simple moving average of $0.98. Gossamer Bio, Inc. has a 52 week low of $0.50 and a 52 week high of $1.55.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). The business had revenue of $9.38 million for the quarter, compared to analysts' expectations of $7.02 million. As a group, equities research analysts predict that Gossamer Bio, Inc. will post -0.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on GOSS. Wedbush reiterated an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a research note on Friday, March 14th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Gossamer Bio in a research report on Tuesday, March 18th. Finally, The Goldman Sachs Group decreased their target price on Gossamer Bio from $8.00 to $7.00 and set a "buy" rating on the stock in a report on Thursday, April 17th.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.